3 options
Problem Solving in Cardiovascular Risk.
- Format:
- Book
- Author/Creator:
- Crook, M. A.
- Language:
- English
- Subjects (All):
- Cardiovascular system--Diseases--Prevention.
- Cardiovascular system--Diseases--Risk factors.
- Cardiovascular system--Diseases.
- Cardiovascular system.
- Causality.
- Dyslipidemias.
- Risk.
- Behavior.
- Disease.
- Behavior and Behavior Mechanisms.
- Epidemiologic Factors.
- Probability.
- Lipid Metabolism Disorders.
- Psychiatry.
- Statistics as Topic.
- Quality of Health Care.
- Public Health.
- Metabolic Diseases.
- Epidemiologic Methods.
- Environment and Public Health.
- Health Care Quality, Access, and Evaluation.
- Health Care Evaluation Mechanisms.
- Nutritional and Metabolic Diseases.
- Investigative Techniques.
- Delivery of Health Care.
- Risk Factors.
- Risk Reduction Behavior.
- Cardiovascular Diseases.
- Hyperlipidemias.
- Medical Subjects:
- Causality.
- Dyslipidemias.
- Risk.
- Behavior.
- Disease.
- Behavior and Behavior Mechanisms.
- Epidemiologic Factors.
- Probability.
- Lipid Metabolism Disorders.
- Psychiatry.
- Statistics as Topic.
- Quality of Health Care.
- Public Health.
- Metabolic Diseases.
- Epidemiologic Methods.
- Environment and Public Health.
- Health Care Quality, Access, and Evaluation.
- Health Care Evaluation Mechanisms.
- Nutritional and Metabolic Diseases.
- Investigative Techniques.
- Delivery of Health Care.
- Risk Factors.
- Risk Reduction Behavior.
- Cardiovascular Diseases.
- Hyperlipidemias.
- Local Subjects:
- Cardiovascular system--Diseases--Prevention.
- Cardiovascular system--Diseases--Risk factors.
- Cardiovascular system--Diseases.
- Physical Description:
- 1 online resource (288 p.)
- Place of Publication:
- Oxford : Clinical Publishing, 2011.
- Language Note:
- English
- Summary:
- This title will help the multiplicity of clinicians who treat increasing numbers of patients with established cardiometabolic disease. It reflects the experiences and challenges that the authors have seen in leading lipid and prevention clinics in primary and secondary care over the last two decades. It will aid in providing answers for those seeking strategies to manage this complex range of symptoms.
- Contents:
- Contents; Preface; Contributors; Abbreviations; SECTION ONE: Primary Prevention; 1 Assessment of Cardiovascular Risk; 2 Morbid Obesity; 3 Metabolic Syndrome; 4 Vegetarian; 5 Indian Asian; 6 African; 7 Polygenic Hypercholesterolaemia; 8 Extremely Elderly; 9 Women; 10 Screening for Hyperlipidaemias and Cardiovascular Risk; 11 Impaired Glucose Tolerance; 12 Low High-density Lipoprotein Cholesterol; 13 Combination Fibrate-Statin Therapy; 14 Low High-density Lipoprotein Cholesterol in Secondary Prevention; SECTION TWO: Secondary Prevention; 15 Coronary Heart Disease; 16 Unstable Angina; 17 Stroke
- 18 Peripheral Vascular Disease19 Aortic Stenosis; 20 Erectile Dysfunction; 21 Atrial Fibrillation; 22 Renal Artery Stenosis; 23 Homocysteine and Cardiovascular Disease; 24 Type1 Diabetes Mellitus; 25 Type2 Diabetes Mellitus; 26 Type2 Diabetes Mellitus and Microalbuminuria; 27 Lipoprotein(a) and Cardiovascular Risk; 28 Chronic Cardiac Failure; SECTION THREE: Secondary Hyperlipidaemias andSide-effects; 29 Hypothyroidism; 30 Alcohol-associated Hyperlipidaemia; 31 Non-alcoholic Fatty Liver Disease; 32 Lipid-lowering Drugs and Rhabdomyolysis; 33 Primary Biliary Cirrhosis
- 34 Multiple Drug Intolerances35 Gastrointestinal Side-effects of Lipid-lowering Drugs; 36 Neuropathy and Statins; SeCTION FOUR: Genetic Hyperlipidaemias; 37 Familial Hypercholesterolaemia; 38 Paediatric Familial Hypercholesterolaemia; 39 Homozygous Familial Hypercholesterolaemia; 40 Familial Combined Hyperlipidaemia; 41 Remnant Hyperlipidaemia; 42 Chylomicronaemia; 43 GlycogenStorage Disease and Dyslipidaemia; 44 Fabry Disease; SECTION FIVE: General Medicine and Hyperlipidaemia; 45 Pregnancy and Hyperlipidaemia; 46 HIV Dyslipidaemia; 47 Autoimmune Disease and Atherosclerosis
- 48 Nephrotic Syndrome49 Chronic Renal Failure; 50 Renal Transplant; 51 Hypopituitarism; SECTION SIX: Hypertension; 52 Hypertension; 53 Resistant Hypertension; 54 Phaeochromocytoma; 55 Hyperaldosteronism; SECTION SEVEN: Dermatological Dyslipidaemia; 56 Retinoid-induced Dyslipidaemia; 57 Mycosis Fungoides, Bexarotene and T-cell Lymphoma; Index
- Notes:
- Description based upon print version of record.
- Includes bibliographical references and index.
- ISBN:
- 1-283-14681-9
- 9786613146816
- 1-84692-633-5
- OCLC:
- 735622776
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.